Navigation Links
Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Date:4/14/2008

SAN FRANCISCO, April 14 /PRNewswire-FirstCall/ -- Positive preclinical data was presented by Nektar Therapeutics (Nasdaq: NKTR) this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse xenograft model of colorectal cancer when co-administered with bevacizumab. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California, the data also featured the enhanced pharmacokinetic profile and tolerability of NKTR-102, as compared to irinotecan in animal models.

NKTR-102 is a PEGylated form of irinotecan developed using Nektar's innovative small molecule PEGylation technology platform. NKTR-102 is currently in a Phase 2 development program to evaluate its safety and efficacy as a second-line colorectal cancer therapy in combination with cetuximab. Nektar had previously announced its intention to expand the NKTR-102 Phase 2 clinical development program later this year with additional indications.

"NKTR-102 is demonstrating important promise as a solid tumor treatment that could be used in a number of critical cancer care regimens," said Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "These data reinforce our confidence in the potential of our small molecule PEGylation technology platform to improve the therapeutic potential of oncolytics that are widely used to treat cancer. We look forward to presenting new data from our clinical trials at additional major oncology conferences this year."

In the preclinical studies presented at AACR, NKTR-102 was co-administered with bevacizumab to evaluate the effects of combination therapy. The combination therapy had an additive effect, inhibiting tumo
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
2. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
3. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
9. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
10. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
11. Evotecs EVT 101 Shown to Penetrate the Brain in Man and to Modulate Brain Activity During the Performance of Cognitive Tasks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Holdings, Inc. today announced that it has been na...Technology Council (NJTC), a 1,200-member non-prof...tworking opportunities, information and advocacy f...earned the award based on criteria including marke... , , "We are delighted that the New Jersey ...
(Date:11/20/2008)... The following is being released by Center for Hea...AIDS Day Audio Media Conference , , WHEN:... EST , Call-in number: 1-800-949-8476 , RSVP...1xe41i2yre8rs , , WHY: With new HIV infe... treatment worldwide, advocates are calling on the...
(Date:11/20/2008)...GlaxoSmithKline (NYSE: ...and Drug Administration (FDA) granted accelerated ...atment of thrombocytopenia in patients with chroni...P) who have had an insufficient response to cortic...roval is a significant milestone for PROMACTA and ...
(Date:11/20/2008)...ire-FirstCall/ -- Arpida (SWX:,ARPN) announced to...ee of the,U.S. Food and Drug Administration (FDA)...enous iclaprim, an antibiotic currently in develop...ed skin and skin structure infections,(cSSSIs), i...phylococcus,aureus (MRSA). , Arpida remain...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Direct Relief International Aims California Fire Response at Health Concerns 4445 1Direct Relief International Aims California Fire Response at Health Concerns 4445 2Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion 4442 1Illinois Planning Board Approves Central DuPage Hospital Bed Pavilion 4442 2IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 1IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 2IdentiPHI Introduces Biometric Authentication Solution for Citrix Web Interface Environments 933 3Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County 4440 1Scripps Health Treats More Than 160 Fire Victims at Emergency Departments Across San Diego County 4440 2
....Y.--(BUSINESS WIRE)--Jun 4, 2007 - Acorda,Therape... the,Company presented a "meta-analysis" or combin...R in multiple sclerosis during a,poster session at...,in MS (ACTRIMS) Meeting in Washington, D.C. on Sa...onsistent Improvement in Walking,Speed on the Time...
...SINESS WIRE)--Jun 4, 2007 - Cytogen Corporation,(N...trials,demonstrating that QUADRAMET (samarium Sm-1...d to prostate cancer patients who are also,receivi...-Aventis).,Clinical data also support further eval...t of prostate cancer in a Phase 2 program.,The res...
Other Medicine Technology:Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 2Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 3Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7
(Date:11/22/2008)...0 don,t do enough to protect themselves from strok...ealthDay News) -- It,s one of medicine,s mantras: ...ower it will have a dramatic impact on your risk o...ent of people with high blood pressure still aren,...g to a U.S. Centers for Disease Control and Preven...
(Date:11/21/2008)...NTY, Calif., Nov. 21 Album Creativ...rm, launches a new program offering big brand mark...ken the large, expensive ad agency process and ser...a very hands-on approach," says Matt Parker, Creat...combines experience and proven brand-building tech...
(Date:11/21/2008)...ASSEE, Fla. -- A Florida State University College ... discovered an important new layer of regulation i...reater understanding of the way cancer begins. , ...es at the College of Medicine, said the findings w... and could lead to the design of new drugs that ki...
(Date:11/21/2008)...iz., Nov. 21 The Provide...nnounced that Craig A. Norris, the Company,s,Chie...pany,s Board of,Directors. Mr. Norris, appointme...nation of Steven I. Geringer and returns the board...y committee of the Board. , Mr. Norris, age...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3
...rkable for its ability to live in the strong acid ...ccoli is powerful against the bacterium that is li.../ It's now well established that this microbe is r...Clearing it with antibiotics is an important form ...
...ggest that, some women who develop gestational dia...en with certain chromosomal abnormalities However,...tself a risk factor for these types of defects sin...l before gestational diabetes typically develops./...
... study on seedless green grapes which caused a sal...x Western states last summer and fall. Researchers...nella serotype senftenberg// most often found in m...to people through grapes. Dr.Alicia, at the Intern...
...utting their lives at risk because they fail to ex...embarrassed to consult their general practitioner ... their argument on a case study involving a young...t and suffered minor injuries. Four days later he ...
Other Medicine News:Health News:Gestational Diabetes linked to Chromosomal defici 2Health News:Grapes, Melons Implicated in Outbreaks 2Health News:Patients with testicular cancer dying through unfamiliarity 2